In resource-constrained settings, getting vaccines safely and reliably to children in remote areas is a daily challenge. Exposure of vaccines to excessive heat or freezing temperatures, which often occurs in such settings, can compromise their potency.
such as pneumococcal conjugate vaccines and rotavirus vaccines, are much more difficult to research, develop and manufacture than traditional vaccines, they are more expensive than these. 15 As costs rise, it becomes increasingly important to manage inventories and minimize open and closed vial wastage. [12] [13] [14] In addition, many new vaccines are presented in a format and packaged in a way that can create handling difficulties for countries with poor infrastructure. Furthermore, the cold chain system, which was designed in the late 1970s to early 1980s for the transport of the six traditional vaccines that existed at the time, lacks the capacity to deal with the much larger number of vaccines that exist today.
In environments with few resources, protecting every child with lifesaving vaccines will not be possible without thoughtful improvement in at least two areas: (i) strengthening national immunization systems and providing support to health workers tasked with delivering vaccines, and (ii) improving vaccine design and presentation.
Although efforts to strengthen country systems are well documented, 16 ,17 little has been published on efforts to influence vaccine design and presentation. This paper describes a novel approach to collaboration between the private and the public sectors, with a focus on ensuring that new vaccines are designed with attention to the needs and problems of national immunization programmes in low-and middle-income countries.
Forum for early discussion
The Vaccine Presentation and Packaging Advisory Group (VPPAG) was established by the GAVI Alliance in 2007 in response to a query from industry about the optimal number of doses per vial for vaccines used in GAVI-eligible countries (low-and lowermiddle-income countries). At the time, there were concerns about the available presentations of the rotavirus and pneumococcal conjugate vaccines that GAVI was planning to support and the VPPAG was asked to provide input and guidance on the presentation and packaging of both vaccines. In 2011, the VPPAG made recommendations to WHO on how to make optimal use of the limited space on vaccine labels and make these easier for vaccinators to read. 23 These recommendations were endorsed by the Advisory Committee and passed along for review by the Expert Committee on Biological Standardization, which has among its responsibilities to oversee policies related to vaccine package labelling. The Expert
Committee on Biological Standardization supported VPPAG's initial recommendations and asked that a more detailed proposal and timeline be developed and submitted to it, at which point it will revise the global regulatory guidance on the basis of the recommendations.
The VPPAG is also conducting research and engaging in discussion on the utility of placing barcodes on vaccine vials for better management of vaccine stock, minimizing packaging volumes, and selecting optimal package sizes to make best use of storage facilities.
Value to public and private sectors
The VPPAG recognizes the need to have discussions about vaccine formulation and packaging much earlier in the process than was previously the norm, since reformulations and changes in the packaging presentations can be extremely costly and problematic. For Until the VPPAG was formed in 2007, there had been no forum where discussions between the public and private sectors could be held openly, where all voices could be considered on an equal footing, and where consensus among all parties could be pursued.
We believe that the VPPAG has made discussion between private and public sectors more productive, expedient and fruitful than they were in the past. Public sector partners now have a better understanding of the cost and market implications of product design and packaging choices. This understanding makes it easier to appreciate trade-offs and request characteristics that will minimize market disruptions while still improving product suitability for developing country contexts. Private sector partners, on the other hand, have come to learn the needs and constraints faced by low-income countries and are increasingly able to design products better suited for these environments. In making critical choices about new products, industry greatly appreciates being able to speak openly and discuss product attributes before investing the time and money required to take a product to market.
The VPPAG's members view the entity as having also generated a sense of trust and partnership between public and private sector representatives and as having provided a venue for general, all-inclusive discussions about product design, formulation, presentation and packaging. All this is of value to donors eager to see vaccine development efforts more clearly meet the needs of immunization programmes in lowand middle-income countries. It is also of value to vaccination programmes in developing countries insofar as it ensures that products developed for their systems will be easier to deploy safely and efficiently.
How it works
The VPPAG holds monthly teleconference meetings chaired by UNICEF and supported by a secretariat at WHO. Meeting participants include representatives from the As the group's work has gained credibility and produced visible impact, other partners, such as the Bill & Melinda Gates Foundation, have made requests to join the VPPAG. The VPPAG itself is extending invitations to key partners and agencies that
were not originally involved in the VPPAG but whose input would be of great value, including the Pan American Health Organization, with its revolving fund.
Others may join the calls, but only designated spokespeople can represent their respective groups. Additionally, the VPPAG creates small working groups to advance specific topics and areas of research. This has made it possible to reach consensus in a way that addresses the interests of both industry and the public sector.
Why it works

Conclusions
The VPPAG is an important forum where stakeholders from the vaccine industry and The VPPAG could provide a model for organizations struggling to meet the needs of markets in both high-and low-income countries. Such organizations would benefit from feedback on product characteristics that could improve product applicability in markets with different infrastructures, and consumers in developing countries could benefit from access to a wider array of suitable products without unnecessary delay.
Having a forum that allows constructive dialogue between the public and private sector furthers our shared goal of preventing disease, disability and death from vaccinepreventable diseases by designing products that can more easily reach those who will most benefit from immunization.
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